Targeted RNA interference of phosphatidylinositol 3-kinase p110-β induces apoptosis and proliferation arrest in endometrial carcinoma cells

Journal of Pathology

Volumn 212, Issue 2, 2007, Pages 161-169

  An, H J ^a   Cho, N H ^b   Yang, H S ^a   Kwak, K B ^a   Kim, N K ^a   Oh, D Y ^a   Lee, S W ^a   Kim, H O ^a   Koh, J J ^a  

^a CHA University   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

Apoptosis; Cell cycle; Endometrial cancer; PI3K p110 ; siRNA

Indexed keywords

AKT1 PROTEIN; CYCLIN E; ISOPROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN KINASE B BETA; PROTEIN P110; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; GENE TARGETING; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; RNA INTERFERENCE; TUMOR GROWTH;

1-PHOSPHATIDYLINOSITOL 3-KINASE; APOPTOSIS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; ISOENZYMES; NEOPLASM PROTEINS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, NEOPLASM; RNA, SMALL INTERFERING;

EID: 34249819647     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2158     Document Type: Article

References (42)

1. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem 1998;67:481-507.
2. Hiles ID, Otsu M, Volinia S, Fry MJ, Gout I, Dhand R, et al. Phosphatidylinositol 3-kinase: structure and expression of the 110 kD catalytic subunit. Cell 1992;70:419-429.
3. Hu P, Mondino A, Skolnik EY, Schlessinger J. Cloning of a novel ubiquitously expressed human phosphatidylinositol 3-kinase and identification of binding site to p85. Mol Cell Biol 1993; 13:7677-7688.
4. Vanhaesebroeck B, Welham MJ, Kotani K, Stein R, Warne PH, Zvelebil MJ, et al. P110 δ, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci U S A 1997;94:4330-4335.
5. Wang Q, Bilan PJ, Tsakiridis T, Hinek A, Klip A. Actin filaments participate in the relocalization of pbosphatidylinositol 3-kinase to glucose transporter containing compartments and in the stimulation of glucose uptake in 3T3-L1 adipocytes. Biochem J 1998; 331:917-928.
6. Bartlett SE, Reynolds AJ, Tan T, Heydon K, Hendry IA. Differential mRNA expression and subcellular locations of PI3-kinase isoforms in sympathetic and sensory neurons. J Neurosci Res 1999; 56:44-53.
7. Bi L, Okabi I, Bernard DJ, Wynshaw-Boris A, Nussbaum RL. Proliferative defects and embryonic lethality in mice homozygous for a deletion in the p110α subunit of phosphoinositide 3-kinase. J Biol Chem 1999; 274:10963-10968.
8. Asano T, Kanda H, Katagiri M, Nawano T, Ohihara K, Inukai M, et al. p110beta is up-regulated during differentiation of 3T3-L1 cells and contributes to the highly insulin-responsive glucose transport activity. J Biol Chem 2000;275:17671-17676.
9. Vanhaesebroeck B, Waterfield MD. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 1999;253:239-254.
10. Zhang Y, Wei L, Wang J, Sun T. Role of phosphatase PTEN in the activation of extracellular signal-regulated kinases induced by estradiol in endometrial carcinoma cells. Chin Med J 2003; 116:383-387.
11. Castoria G, Migliaccio A, Bilancio A, Di Domenic M, deFalco A, Lombardi M, et al. PI3-kinase in concert with src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J 2001; 20:6050-6059.
12. Kayisli OG, Kayisli UA, Luleci G, Arici A. In vivo and in vitro regulation of AKT activation in human endometrial cells is estrogen dependent. Biol Reprod 2004;71:714-721.
13. Risinger JI, Hayes AK, Berchuck A, Barrett JC. PTEN/MMMAC1 mutations in endometrial cancers. Cancer Res 1997;57:4736-4738.
14. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997; 57:3935-3940.
15. Ellenson LH. The molecular biology of endometrial tumorigenesis: does it have a message? Int J Gynecol Pathol 2000;19:310-313.
16. Mutter GL, Ling MC, Fitzgerald JT, Kum JB, Baak JPA, Lees JA, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92:924-930.
17. Nakatani K, Thompson DA, Bartrhel A, Sakaue H, Liu W, Weigel RJ, et al. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 1999;274:21528-21532.
18. Kanamori Y, Kiawa J, Itamochi H, Shimada M, Takahashi M, Kamazawa S, et al. Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin Cancer Res 2001; 7:892-895.
19. Zhang L, Yang N, Katasaros K, Huang W, Park JW, Fracchioli S, et al. The oncogene phosphatidylinositol 3′-kinase catalytic sub-unit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma. Cancer Res 2003;63:4225-4231.
20. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005;65:2554-2559.
21. Oda K, Stokoe D, Taketani Y, McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 2005;65:10669-10673.
22. Semba S, Itoh N, Ito M, Harada M, Yamakawa M. The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3′-kinase, in human colon cancer cells. Clin Cancer Res 2002;8: 1957-1963.
23. Fan QW, Specht KM, Zhang C, Goldenberg DD, Shokt KM, Weiss WA. Combinatorial efficacy achieved through two-point blockade within signaling pathway - a chemical genetic approach. Cancer Res 2003;63:8930-8938.
24. Sourbier C, Lindner V, Lang H, Agouni A, Shordan E, Danilin S, et al. The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy. Cancer Res 2006;66:5130-5142.
25. Jones PF, Jakubowicz T, Pitossi FJ, Maurer F, Hemmings BA. Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc Natl Acad Sci U S A 1991; 88:4171-4175.
26. Bellacosa A, Testa JR, Staal SP, Tsichlis PN. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 1991;254:274-277.
27. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999;13:2905-2977.
28. Yuan ZQ, Sun M, Feldmann RI, Wang G, Ma X, Jian C, et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 2000;19:2324-2330.
29. Kane LP, Shapiro VS, Stokoe D, Weiss A. Induction of NF-kappa B by the Akt/PKB kinase. Curr Biol 1999;9:601-604.
30. Gao N, Flynn DC, Zhang Z, Zhong XS, Walker V, Liu KJ, et al. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol 2004;287:C281-C291.
31. Lavoie IN, L'Allemain G, Brunet A, Muller R, Pouyssegur J. Cyclin D1 expression is regulated positively by the p42/p44 MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 1996;271:20 608-20 616.
32. Balmanno K, Cook SJ. Sustained MAP kinase activation is required for the expression of cyclin D1, p21, Cip1 and a subset of AP-1 proteins in CCL39 cells. Oncogene 1999;18:3085-3097.
33. Liang J, Slingerland JM. Multiple roles of the PI3K/PKB(Akt) pathway in cell cycle progression. Cell Cycle 2003;2:339-345.
34. Li Y, Dowbenko D, Lasky LA. AKT/PKB phosphorylation of p21 Cip/WAF1 enhances protein stability of p21 Cip/WAF1 and promotes cell survival. J Biol Chem 2002;277:11 352-11 361.
35. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. Cytoplasmic localization of p21 Cip/WAF1 by Akt-induced phosphorylation in HER-2/ neu-overexpressing cells. Nature Cell Biol 2001;3:245-252.
36. Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D, et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p21(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nature Med 2002; 8:1136-1144.
37. Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, et al. PKB/ Akt mediates cell-cycle progression by phosphorylation of p21(Kip1) at threonine 157 and modulation of its cellular localization. Nature Med 2002;8:1145-1152.
38. Welcker M, Lukas J, Strauss M, Bartek J. p21 WAF1/CIP1 mutants deficient in inhibiting cyclin-dependent kinases (CDKs) can promote assembly of active cyclinD/CDK4(6) complexes in human tumor cells. Cancer Res 1998;58:5053-5056.
39. Downward J. PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 2004;15:177-182.
40. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in auti-apoptotic PDGF signalling. Nature 1999;401:86-90.
41. Wang CY, Guttridge DC, Mayo MW, Baldwin AS Jr. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999; 19:5923-5929.
42. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumor necrosis factor requires the Akt serine-threonine kinase. Nature 1999;401:82-85.